Summary & Overview

HIV with or without Other Related Condition: Inpatient Reimbursement Overview

DRG 977 addresses inpatient stays for human immunodeficiency virus infection with or without related conditions, including management of opportunistic infections and HIV-related complications. It matters for inpatient reimbursement because Diagnosis-Related Group assignment and documentation of related conditions determine Medicare payment grouping and resource-based hospital reimbursement.

HIV with or without Other Related ConditionDRG HIV with or without Other Related ConditionDRG 977Diagnosis-Related GroupInpatient ReimbursementMedicareInfectious DiseaseInternal MedicineOpportunistic InfectionsHospital Coding

DRG 977 Overview

DRG 977 covers inpatient admissions for human immunodeficiency virus infection with or without other related conditions, encompassing primary HIV disease management and associated opportunistic infections or complications. This Diagnosis-Related Group is relevant to inpatient reimbursement because payment is grouped by the principal diagnosis and any documented complications or comorbidities that influence resource use. Accurate coding of HIV and related conditions affects case categorization and the Medicare Severity Diagnosis-Related Group payment assignment. The classification guides hospital billing and reflects clinical complexity during the hospitalization.

Clinical Trials

Acute inpatient antiretroviral management studies: trials in this area evaluate strategies for initiating, modifying, or safely interrupting antiretroviral therapy (ART) during hospitalization for HIV-related or unrelated acute illnesses. Populations include people with newly diagnosed HIV identified during admission, those admitted with opportunistic infections or severe immune suppression, and patients with drug–drug interaction risks from concurrent inpatient therapies. These studies are relevant to clinicians and payers because inpatient ART decisions affect length of stay, complications, readmission risk, and downstream outpatient resource use and costs.
Comparative effectiveness and safety studies of co-infection and comorbidity management: research focused on comparing approaches to diagnosing and managing common inpatient co-conditions (for example, tuberculosis, hepatitis B or C, pneumocystis pneumonia, severe bacterial infections, and cardiopulmonary comorbidities) in people with HIV. These trials or observational comparative studies enroll hospitalized HIV-positive patients with specific co-infections or organ dysfunction to assess outcomes such as mortality, time to clinical stability, adverse events, and need for intensive care. The findings inform hospital protocols, utilization of specialty services, and payer decisions about bundled care pathways and appropriate resource allocation for complex patients in this DRG.
Transitional care, adherence, and health systems outcomes research: interventions tested in this area aim to reduce readmissions and improve linkage to outpatient HIV care after discharge, including models like enhanced discharge planning, case management, telehealth follow-up, and interventions addressing social determinants of health. Study populations are discharged inpatients with HIV who have unstable housing, substance use, mental health comorbidity, or prior gaps in care; endpoints include retention in care, viral suppression, readmission rates, and cost-effectiveness. This research is highly relevant to providers and payers because effective transitional interventions can lower avoidable rehospitalizations, improve long-term outcomes, and optimize reimbursement and care management strategies for the DRG.

Clinical Trials

Acute inpatient antiretroviral management studies: trials in this area evaluate strategies for initiating, modifying, or safely interrupting antiretroviral therapy (ART) during hospitalization for HIV-related or unrelated acute illnesses. Populations include people with newly diagnosed HIV identified during admission, those admitted with opportunistic infections or severe immune suppression, and patients with drug–drug interaction risks from concurrent inpatient therapies. These studies are relevant to clinicians and payers because inpatient ART decisions affect length of stay, complications, readmission risk, and downstream outpatient resource use and costs.
Comparative effectiveness and safety studies of co-infection and comorbidity management: research focused on comparing approaches to diagnosing and managing common inpatient co-conditions (for example, tuberculosis, hepatitis B or C, pneumocystis pneumonia, severe bacterial infections, and cardiopulmonary comorbidities) in people with HIV. These trials or observational comparative studies enroll hospitalized HIV-positive patients with specific co-infections or organ dysfunction to assess outcomes such as mortality, time to clinical stability, adverse events, and need for intensive care. The findings inform hospital protocols, utilization of specialty services, and payer decisions about bundled care pathways and appropriate resource allocation for complex patients in this DRG.
Transitional care, adherence, and health systems outcomes research: interventions tested in this area aim to reduce readmissions and improve linkage to outpatient HIV care after discharge, including models like enhanced discharge planning, case management, telehealth follow-up, and interventions addressing social determinants of health. Study populations are discharged inpatients with HIV who have unstable housing, substance use, mental health comorbidity, or prior gaps in care; endpoints include retention in care, viral suppression, readmission rates, and cost-effectiveness. This research is highly relevant to providers and payers because effective transitional interventions can lower avoidable rehospitalizations, improve long-term outcomes, and optimize reimbursement and care management strategies for the DRG.

OpenPayer

Summary & Overview

HIV with or without Other Related Condition: Inpatient Reimbursement Overview

DRG 977 Overview

Clinical Trials

Related Codes

Clinical Trials

Related Codes